Who is sponsoring NCT05137158?

NCT05137158 is sponsored by Central South University.

What drugs are being tested in NCT05137158?

Interventions in NCT05137158: Intermittent theta burst stimulation, Sham stimulation.

What condition does NCT05137158 study?

NCT05137158 studies Schizophrenia.

Is NCT05137158 still recruiting?

NCT05137158 is currently completed. Last updated 20 August 2024.

Last reviewed 2024-08-20 · How we verify

NCT05137158

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

iTBS on Negative Symptoms and Cognitive Function in Schizophrenia

Completed NA Last updated 20 August 2024

What this trial tests

NA trial testing Intermittent theta burst stimulation in Schizophrenia in 66 participants. Completed in 14 June 2024.

Timeline

15 October 2022

Primary endpoint
14 June 2024

14 June 2024

Quick facts

Lead sponsor	Central South University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	66
Start date	15 October 2022
Primary completion	14 June 2024
Estimated completion	14 June 2024
Sites	1 location across China

Drugs / interventions tested

Intermittent theta burst stimulation
Sham stimulation

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Central South University

Who can join

Adults 18 to 60, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The negative symptoms and cognitive deficits are common in patients with schizophrenia, and do not respond well to antipsychotics. The effective treatments for negative symptoms and cognitive impairment are still to be explored. rTMS is a safe and non-invasive physical treatment, some studies has been indicated that the high frequency rTMS could increase the excitability of cortex, and has potentials to improve negative symptoms and cognitive function in schizophrenia. In this study, we explore the effects of iTBS on negative symptoms and cognitive function based on identifying the brain network connection of schizophrenia symptoms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Accelerated Intermittent Theta Burst Stimulation Targeting the Superior Frontal Gyrus on Cognitive Function in Patients With Schizophrenia: A Double-Blind, Randomized, Sham-Controlled Clinical Trial.
Peng X, Song C, Su Y, Kang D, et al · · 2026 · PMID 40653187 · DOI 10.1016/j.biopsych.2025.06.034

Verify or expand the search:

Other trials of Intermittent theta burst stimulation

Trials testing the same drug.

NCT07452939 — Prefrontal Theta Burst Stimulation to Improve Cognitive Impairment After ICU Delirium · NA · recruiting
NCT05860647 — Transmagnetic Stimulation Pilot in Primary Progressive Aphasia · NA · completed
NCT05292222 — Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease · NA · completed
NCT04658745 — Effects of Theta Burst Stimulation on Modulation of Mirror Illusion-induced Rhythm Suppression in Stroke · NA · completed
NCT03277521 — Theta Burst Stimulation to Promote Motor Re-education in Tetraplegia · NA · completed

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Central South University trials

Trials by the same sponsor.

NCT07444463 — Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications · NA · not yet recruiting
NCT07446478 — TIS for Improving Cognitive Impairment Associated With Schizophrenia · NA · not yet recruiting
NCT07045142 — Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients · Phase 3 · recruiting
NCT07066813 — Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces · recruiting
NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05137158 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central South University
Last refreshed: 20 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05137158.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing